<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637221</url>
  </required_header>
  <id_info>
    <org_study_id>NPL-2009-2-FEN-001</org_study_id>
    <nct_id>NCT00637221</nct_id>
  </id_info>
  <brief_title>Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome</brief_title>
  <official_title>An Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label exploratory study to investigate the safety and effects of a single&#xD;
      dose of NPL-2009(50 mg - 150 mg) on Prepulse Inhibition (PPI) Tests and Continuous&#xD;
      Performance Tasks (CPT) in adults with Fragile X Syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure for the study is that of safety and subjects will be assessed post-dose at at least hourly intervals for any signs of Adverse Events - up to allowing discharge from the unit at 6 hours post-dose</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Fragile X Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPL-2009</intervention_name>
    <description>Single doses of either 50mg, 100 mg or 150 mg NPL-2009</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, 18 to 45 years of age.&#xD;
&#xD;
          -  Diagnosis of Fragile X Syndrome.&#xD;
&#xD;
          -  Females must demonstrate a negative pregnancy test at screening.&#xD;
&#xD;
          -  Females of child-bearing potential must be using a medically accepted means of&#xD;
             contraception or must remain abstinent for the duration of the study.&#xD;
&#xD;
          -  Each Legally Authorised Representative (LAR, usually parent or caregiver) must have a&#xD;
             level of understanding sufficient to provide written informed consent to all required&#xD;
             study tests and procedures.&#xD;
&#xD;
          -  Each patient must consent/assent (depending on center-specific procedures) to all&#xD;
             required study tests and procedures.&#xD;
&#xD;
          -  Permitted concomitant medications must be stable for at least 6 weeks prior to&#xD;
             enrollment. The following concomitant medications are permitted: psychostimulants,&#xD;
             SSRIs, atypical antipsychotics, anticonvulsants which do not have liver inducing&#xD;
             effects, clonidine.&#xD;
&#xD;
          -  Each patient must be able to swallow the capsules (2, 3 or 4) to be provided in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment with anticonvulsants known to induce liver enzymes e.g. depakote&#xD;
&#xD;
          -  Current treatment with N-methyl-D-aspartate (NMDA) antagonists&#xD;
&#xD;
          -  Current treatment with tricyclic antidepressants&#xD;
&#xD;
          -  Current treatment with typical antipsychotics&#xD;
&#xD;
          -  Current treatment with lithium&#xD;
&#xD;
          -  Patients planning to commence cognitive behaviour therapy during the period of the&#xD;
             study or those who have begun cognitive behavioural therapy within 6 weeks prior to&#xD;
             enrolment.&#xD;
&#xD;
          -  History of, or current cardiovascular, renal, hepatic, respiratory and particularly&#xD;
             gastrointestinal disease which may interfere with the absorption, distribution,&#xD;
             metabolism or excretion of the study medication.&#xD;
&#xD;
          -  History of, or current cerebrovascular disease or brain trauma.&#xD;
&#xD;
          -  History of, or current significant endocrine disorder, e.g. hypo or hyperthyroidism.&#xD;
&#xD;
          -  History of, or current malignancy.&#xD;
&#xD;
          -  Presence of psychotic symptoms or lifetime history of schizophrenia, bipolar disorder,&#xD;
             or other psychotic disorder, as assessed by the Investigator.&#xD;
&#xD;
          -  Current major depressive disorder (patients must be free of the disorder for 3 months&#xD;
             prior to enrolment).&#xD;
&#xD;
          -  Judged clinically to be at risk of suicide (suicidal ideation, severe depression, or&#xD;
             other factors), as assessed by the Investigator.&#xD;
&#xD;
          -  Tourette's Disorder.&#xD;
&#xD;
          -  Female patients who are either pregnant or nursing.&#xD;
&#xD;
          -  Current drug abuse or dependence disorder or dependency in the 3 months prior to&#xD;
             enrolment.&#xD;
&#xD;
          -  Clinically significant abnormalities in safety laboratory tests, vital signs or EKG,&#xD;
             as measured at screening&#xD;
&#xD;
          -  Patients with significant hearing and/or visual impairments that may affect their&#xD;
             ability to complete the test procedures&#xD;
&#xD;
          -  Enrollment in another clinical trial within the previous 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Snape, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neuropharm Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MIND Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Centre</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2008</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

